ENDONOVO THERAPEUTICS, INC. (ENDV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q4 '12: 30.6K Q1 '13: 28.9K Q2 '13: 20.8K Q3 '13: 13.7K Q4 '13: 22.9K Q1 '14: 40.7K Q2 '14: 57.1K Q3 '14: 77.7K Q4 '15: 4.3K Q1 '16: 1.5K Q4 '18: 83.3K Q1 '19: 121.2K Q2 '19: 171.1K Q3 '19: 203.9K Q4 '19: 310.2K Q1 '20: 334.9K Q2 '20: 316.8K Q3 '20: 302.7K Q4 '20: 165.8K Q1 '21: 130.8K Q2 '21: 116.5K Q3 '21: 84.3K Q4 '21: 73.1K Q1 '22: 40.7K Q2 '22: 11K Q3 '22: 14.2K Q4 '22: 135.4K Q1 '23: 220.6K Q2 '23: 265.2K Q3 '23: 255.7K Q1 '13 Q1 '14 Q1 '16 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23

Gross Profit TTM

0 90K 180K 270K Q4 '15: 2.1K Q1 '16: 182 Q4 '18: 70.3K Q1 '19: 100.6K Q2 '19: 121.5K Q3 '19: 149.6K Q4 '19: 216.8K Q1 '20: 243K Q2 '20: 243.1K Q3 '20: 237.2K Q4 '22: 125.4K Q1 '23: 207.3K Q2 '23: 252.3K Q3 '23: 246K Q1 '16 Q1 '19 Q3 '19 Q1 '20 Q3 '20 Q1 '23 Q3 '23

Operating Income TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '12: -1.7M Q1 '13: -2.3M Q2 '13: -2.4M Q3 '13: -2.5M Q4 '13: -2.4M Q1 '14: -2M Q2 '14: -2.3M Q3 '14: -2.5M Q4 '14: -2.2M Q1 '15: -2.1M Q2 '15: -1.7M Q3 '15: -1.6M Q4 '15: -2.6M Q1 '16: -3.6M Q2 '16: -5.2M Q3 '16: -6M Q4 '16: -5.4M Q1 '17: -4.6M Q2 '17: -4.7M Q3 '17: -4.4M Q4 '17: -4.6M Q1 '18: -5.3M Q2 '18: -4M Q3 '18: -4M Q4 '18: -4.2M Q1 '19: -3.7M Q2 '19: -3.9M Q3 '19: -4.1M Q4 '19: -3.8M Q1 '20: -3.7M Q2 '20: -3.3M Q3 '20: -3M Q4 '20: -2.9M Q1 '21: -2.8M Q2 '21: -2.8M Q3 '21: -2.5M Q4 '21: -2.2M Q1 '22: -2.1M Q2 '22: -3.4M Q3 '22: -3.2M Q4 '22: -3.3M Q1 '23: -3.3M Q2 '23: -2.6M Q3 '23: -2.6M Q1 '13 Q3 '14 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '12: -1.8M Q1 '13: -2.5M Q2 '13: -2.7M Q3 '13: -2.7M Q4 '13: -2.9M Q1 '14: -2.4M Q2 '14: -2M Q3 '14: -1.4M Q4 '14: -959.5K Q1 '15: -811.1K Q2 '15: -1.2M Q3 '15: -2.5M Q4 '15: -6.8M Q1 '16: -7.3M Q2 '16: -8.2M Q3 '16: -9.1M Q4 '16: -5.3M Q1 '17: -12.2M Q2 '17: -8.9M Q3 '17: -13.3M Q4 '17: -10.8M Q1 '18: -3.7M Q2 '18: -6.8M Q3 '18: -6M Q4 '18: -6.4M Q1 '19: -8.2M Q2 '19: -14.8M Q3 '19: -10.3M Q4 '19: -17.3M Q1 '20: -10.6M Q2 '20: -4.4M Q3 '20: -4M Q4 '20: -395.6K Q1 '21: -7.4M Q2 '21: -7.1M Q3 '21: -7.5M Q4 '21: -3.1M Q1 '22: -2.8M Q2 '22: -4.1M Q3 '22: -3.1M Q4 '22: -18.5M Q1 '23: -8.8M Q2 '23: -4.2M Q3 '23: -4.4M Q1 '13 Q3 '14 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23

Cost of Revenue TTM

0 35K 70K 105K Q1 '19: 20.6K Q2 '19: 49.7K Q3 '19: 54.3K Q4 '19: 93.4K Q1 '20: 91.9K Q2 '20: 73.7K Q3 '20: 65.5K Q4 '20: 65.4K Q1 '21: 61.6K Q2 '21: 50.8K Q3 '21: 53.2K Q4 '21: 15K Q1 '22: 13.2K Q2 '22: 13.1K Q3 '22: 14K Q4 '22: 10K Q1 '23: 13.3K Q2 '23: 12.9K Q3 '23: 9.7K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Operating Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '12: -284.9K Q1 '13: -380.8K Q2 '13: -264.3K Q3 '13: -259.4K Q4 '13: -257.4K Q1 '14: -337.1K Q2 '14: -567.3K Q3 '14: -735.2K Q4 '14: -909.3K Q1 '15: -907.2K Q2 '15: -802.7K Q3 '15: -1M Q4 '15: -1M Q1 '16: -1.3M Q2 '16: -1.7M Q3 '16: -2M Q4 '16: -2.5M Q1 '17: -2.5M Q2 '17: -2.8M Q3 '17: -2.8M Q4 '17: -3M Q1 '18: -3.1M Q2 '18: -3M Q3 '18: -3M Q4 '18: -2.9M Q1 '19: -2.8M Q2 '19: -2.8M Q3 '19: -2.9M Q4 '19: -2.5M Q1 '20: -2.3M Q2 '20: -1.8M Q3 '20: -857.1K Q4 '20: -741.6K Q1 '21: -734.3K Q2 '21: -715.4K Q3 '21: -788.1K Q4 '21: -986.6K Q1 '22: -819.6K Q2 '22: -890.1K Q3 '22: -844.6K Q4 '22: -678.8K Q1 '23: -729K Q2 '23: -688.4K Q3 '23: -629.9K Q1 '13 Q3 '14 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23

Free Cash Flow TTM

-3M -2M -1M 0 1M 2M 3M Q4 '18: -2.9M Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q1 '11: 0 Q1 '12: 40.5M Q2 '12: 48.4M Q3 '12: 51.2M Q1 '13: 47.1M Q2 '13: 68.7M Q3 '13: 73.1M Q2 '16: 111.8M Q2 '17: 330.8M Q2 '18: 347.9M Q1 '19: 481.8K Q2 '19: 577.5K Q3 '19: 777.2K Q1 '20: 11.9M Q2 '20: 9.8M Q3 '20: 16.1M Q1 '21: 41.6M Q2 '21: 58.5M Q3 '21: 66.3M Q1 '22: 79M Q2 '22: 134.4M Q3 '22: 153.6M Q1 '23: 1.7B Q2 '23: 1.4B Q3 '23: 1.4B Q1 '11 Q1 '13 Q2 '17 Q3 '19 Q1 '21 Q2 '22 Q3 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '12: -0.04 Q1 '13: -0.05 Q2 '13: -0.05 Q3 '13: -0.05 Q4 '13: -3.97 Q1 '14: -3.96 Q2 '14: -3.69 Q3 '14: -3.68 Q4 '15: -0.08 Q1 '16: -0.08 Q2 '16: -0.08 Q3 '16: -0.09 Q4 '16: -0.05 Q1 '17: -0.09 Q2 '17: -0.07 Q3 '17: -0.08 Q4 '17: -0.04 Q1 '18: 0.01 Q2 '18: 0.00 Q3 '18: 0.01 Q4 '18: -17.76 Q1 '19: -22.75 Q2 '19: -36.32 Q3 '19: -38.11 Q4 '19: -45.18 Q1 '20: -40.33 Q2 '20: -26.93 Q3 '20: -25.19 Q4 '20: -0.03 Q1 '21: 0.05 Q2 '21: 0.20 Q3 '21: 0.25 Q4 '21: -0.05 Q1 '22: -0.02 Q2 '22: -0.02 Q3 '22: 0.00 Q4 '22: -0.13 Q1 '23: -0.10 Q2 '13 Q3 '14 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.